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Fluoropyrimidines, oxaliplatin, irinotecan and biologic therapies (Bevacizumab, Panitumumab, and Cetuximab)
represent the backbone of metastatic colorectal cancer (CRC) treatment. The improvement in survival for mCRC
patient led to two main outstanding issues: 1) there is a significant number of patients progressing beyond the
third or fourth line of treatment still suitable for further therapy when enrollment into clinical trial is not possible. In
this situation, the role of any therapy rechallenge (either chemotherapy alone, chemotherapy and biologic therapy
or biologic therapy alone) is still not clear, particularly in patients who had previously responded, and if treatment
choice is based on traditional dogma of primary and secondary resistance, rechallenge does not seem to be
justified. 2) Prolonged intensive treatment is burdened from the high risk of cumulative toxicity, worsening in
quality of life and a not well defined possibility of early acquired resistance.
Different hypothesis could justify the research of different strategy in treatment of mCRC:
1) Epigenetic changes might drive resistance and treatment could induce these changes. Re-expression of silenced
tumor suppressive genes might resensitize tumors to therapy. It is therefore possible that a drug holiday (intermittent
treatment) could allow reversion to a previous epigenetic profile. Moreover an intermittent treatment could delay
acquired resistance. 2) It is plausible that tumor grows as a polyclonal mass. If it responds but then becomes resistant
to one or more treatments, retreatment might be successful if changing therapies allows to that clone of cells to
re-emerge. On these basis, we focused this review on the actual evidences in management of mCRC patients in terms
of chemotherapy or biological therapies rechallenge and intermittent treatment. Moreover, we will discuss the
potential biological mechanisms of the observed results of early clinical trials.
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Colorectal cancer (CRC) accounts for approximately three
hundred thousand deaths worldwide every year. In
metastatic CRC (mCRC), 5-year survival is only 6%
worldwide, 11, 6% in US population and the identification
of reliable prognostic factors in this disease has been an
important focus of research in the last decade [1].
For decades fluoropyrimidines formed the backbone
of treatment in mCRC. The relatively recent introduction of
oxaliplatin, irinotecan and biologic therapies (Bevacizumab,
Panitumumab and Cetuximab) allowed to reach the* Correspondence: g.tonini@unicampus.it
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stated.median overall survival of 23–24 months and up
today monoclonal antibodies combined with standard
chemotherapy are recommended for management of
mCRC [2]. But the improvement in survival for mCRC
patient led to two main outstanding issues: 1) there is a
significant number of patients progressing beyond the
third or fourth line of treatment still suitable for further
therapy when enrollment into clinical trial is not possible.
In this situation, the role of any therapy rechallenge (either
chemotherapy alone, chemotherapy and biologic therapy
or biologic therapy alone) is still not clear, particularly in
patients who had previously responded, and if treatment
choice is based on traditional dogma of primary and
secondary resistance, rechallenge does not seem to be
justified. 2) Prolonged intensive treatment is burdenedtd. This is an Open Access article distributed under the terms of the Creative
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quality of life and a not well defined possibility of early
acquired resistance.
According to a traditional dogma in medical oncology,
a CRC patient is defined as resistant to treatment if the
disease fails to respond (primary resistance) or initially
responds and then progresses (secondary resistance) on
a specific chemotherapy drug or regimen. Therefore,
rechallenging patients’ disease with a drug or drugs to
which their tumors are resistant seems to be inadvisable.
Recently two different strategies are emerging in mCRC
treatment which seem to refute the traditional dogma
of irreversible acquired resistance suggesting different
possibilities to reverse or maintain the chemotherapy
sensitiveness.
Rechallenge therapy as a rescue possibility to
reverse acquired resistance in highly pretreated
mCRC patient
Definition of rechallenge therapy
Rechallenge therapy is defined as reintroduction, after
an intervening treatment, of the same therapy to which
tumor has already proved to be resistant. To our know-
ledge, there are few evidences of mCRC sensitivity to
any rechallenged therapy (Table 1).
Biological rationale and first preclinical evidences of
anti-EGFR rechallenge efficacy
CRC is a complex disease involving many dysregulatory
phenomena in a number of signal transduction pathways
[3]. It has been shown that epidermal growth factor
receptor (EGFR), a tyrosine kinase receptor belonging to
the ErbB family, is overexpressed in 25%–80% of CRCs
and plays a major role in its pathogenesis [4].
Subsequently, several clinical trials have demonstrated
the therapeutic efficacy of antibodies targeting EGFR
(cetuximab and panitumumab) in the treatment of CRC
patients [5]. However, the overall response rate (ORR) to
cetuximab or panitumumab based regimens is less than
30%, suggesting that primary resistance mechanisms are
present in many cases [6-19]. The determination of
Kirsten Rat sarcoma viral oncogene homologue (K-Ras)
gene mutational status through different molecular tech-
niques has recently became essential for the management
of CRC patients as in other human neoplasia [20,21].
Several retrospective and prospective analysis showed
that mutations K-Ras could justify primary resistance
to anti-EGFR therapy [22-25], but molecular basis ofTable 1 Definition of rechallenge therapy and intermittent th
Definition of rechallenge
therapy
Reintroduction, after an intervening treatment, o
Definition of intermittent
therapy
Interruption of treatment without any evidence
a good quality of life and tumor sensitivity.secondary resistance to anti-EGFR therapy are not
understood.
Previous studies suggest that K-Ras mutation is an early
pathogenic step in colorectal cancer development and
remain the same during tumor progression [26]. In fact,
the same K-Ras mutations can be detected in most
adenoma and in more than a half of the tumor adjacent
mucosa [27]. One study provided first evidence that
secondary K-Ras mutations do not occur during anti-
EGFR therapy in CRC patients preserving a potential
sensibility to cetuximab or panitumumab rechallenge [28].
Moreover a recent study from Baldus et al. evaluated
K-Ras, BRAF and PI3K gene status into the primary tumor,
comparing the tumor center and the invasion fronts
showing that intratumoral heterogeneity of K-Ras, BRAF,
and PIK3CA mutations was observed in 8%, 1%, and 5%
of primary tumors, respectively [29].
Conflicting clinical evidences of the activity of anti-EGFR
therapy rechallenge
Given these evidences, a multicenter phase II prospective
study investigated the activity of a rechallenge with a
cetuximab-based therapy in 39 patients who first had
a clinical benefit after a line of cetuximab plus irinotecan-
based therapy, then a disease progression for which
received a new line of chemotherapy and finally, after a
further progression of disease, were re-treated with the
same cetuximab plus irinotecan based therapy. Treatment
holiday was not allowed. Median time to progression with
first treatment with cetuximab was 10 months, the median
interval time between last cycle of first cetuximab-based
therapy and first cycle of the following cetuximab
retreatment was 6 months. Moreover, ORR was 53.8%
with 19 partial responses (48.7%) and 2 complete re-
sponses (5.1%). The median time to progression (TTP)
was 6.6 months, stable disease (SD) was obtained in 35.9%
of patients and progression in 4 (10.2%), and 18 patients
(46.1%) showed the same type of response (SD, partial
response or complete response) during cetuximab retreat-
ment when compared with the response obtained during
the first cetuximab-based therapy. Then stable disease
lasting at least 6 months and partial response during the
first cetuximab-based therapy have been demonstrated to
predict clinical benefit after cetuximab retreatment [30].
Conversely, a subsequent phase II prospective study,
including twenty patients treated with panitumumab
after progression on prior cetuximab-based therapy, did
not show any response to panitumumab being stableerapy
f the same therapy to which tumor has already proved to be resistant
of tumor resistance in order to avoid cumulative toxicities and maintain
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response in 45% of patients [31]. This study showed
that panitumumab has a minimal effect after disease
progression on cetuximab; however, no interval therapy
or treatment holiday were permitted between cetuximab
and panitumumab administration.
Diaz Jr et al. evaluated the variation of circulating tumor
DNA (ctDNA) in serum of 24 patient receiving single-
agent therapy with panitumumab. K-Ras mutations were
recorded in 38% of cases between 5–6 months following
treatment and mathematical modelling indicated that
mutations were present in expanded subclones before the
initiation of treatment. These results suggest that the
emergence of KRAS mutations is a mediator of acquired
resistance to EGFR blockade [32]. Consistently, another
small study showed that point mutations of K-Ras are
casually associated with the onset of acquired resistance
to anti-EGFR therapy. In fact analysis of metastasis from
ten patients who developed resistance to cetuximab or
panitumumab showed the emergence of K-Ras mutant
alleles were detectable in the blood months before the
radiographic documentation of disease progression,
and the in vitro model confirmed the hypothesis of
continuing mutagenesis under the pressure of anti-EGFR
therapy [33].
These studies underlined the possibility of late ac-
quisition of K-Ras secondary mutations under anti EGFR
therapy but still do not confute the possibility of a
rechallenge. In fact an interval therapy after first pro-
gression to the anti-EGFR therapy could restore a partial
sensitivity of tumor to the rechallenge by promoting
the expansion of K-Ras wild-type clones returning,
which will constitute the major part of the tumor
mass at the time of a following progression of dis-





Figure 1 K-Ras WT clone restored during intervening chemotherapy atherapy may then determine a further disease response
(Figure 1).
In this sense an interval therapy based on a different
treatment, which is not influenced by K-Ras status or is
more efficacious in K-Ras mutated CRC, could facilitate
the re-emersion of wt clones (Table 2).
An in vitro model suggested that K-Ras mutated cell
lines are more sensitive to Oxaliplatin [34]. Consistently,
a retrospective study evaluating K-Ras status in 90
patients treated with FOLFOX-6 as first-line or second-
line treatment showing that PFS was longer in mutated
K-Ras population than in wt K-Ras patients (10 vs
8 months, respectively; p = 0.001) [35].
Clinical evidence of activity of standard chemotherapy
rechallenge
The RE-OPEN phase II study assessed the efficacy of the
re-introduction of oxaliplatin (administered in FOLFOX
regimen) for 18 patients with metastatic colorectal
cancer refractory to standard chemotherapy regimens
including oxaliplatin, irinotecan and fluorouracil. Disease
control rate (DCR) after 12 weeks was observed in seven
patients (38.9%) [36].
Treatment holiday and chemotherapy-free
interval strategies
Rationale
The introduction of biologic compounds in combination
with standard chemotherapy in the treatment of mCRC
has extended median overall survival of patients up to
2 years and beyond. Moreover a sequential treatment
approach using all active agents can allow to reach
long-term control of disease changing mCRC from an
acute to chronic condition. In this new scenario, the











llow the gain of new sensibility to anti-EGFR chemotherapy.






K-ras mutation is an early pathogenic step in colorectal cancer development and the
possibility of late acquisition of K-Ras mutation is not clarified. The following therapy could
allow K-Ras WT clone to re-predominate
Treatment holiday
Holiday from a drug could allow reversion to a previous epigenetic profile. Moreover
treatment holiday could facilitate recovery from cumulative toxicity induced by chemotherapy.
To our knowledge few studies evaluated role of treatment holiday and they reported results.
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management.
Several randomized phase III studies evaluated the role
of chemotherapy in mCRC but most of them planned
treatment to be continued until disease progression or
development of intolerable toxicity. Starting from these
evidences, mCRC patients will spend most of their
remaining life receiving continuous anti-tumor therapy,
with the associated toxic effects, periodic clinic visits
detriment to quality of life.
Recently, some studies have investigated the role of
intermittent chemotherapy in order to permit treatment
holiday avoiding cumulative toxicity and preserving a
good quality of life. Moreover, other new studies analyzed
the role of biological agents (bevacizumab or cetuximab)
given as an intervening therapy during chemotherapy
holiday.
Most importantly, giving these therapies for a restricted
period and then restart with or without evidence of
disease progression in the interval is a potential method
for reducing the emergence of acquired resistance to
chemotherapy. In fact epigenetic instability belonging to
tumoral mass might drive resistance under treatment
selective pressure. It is therefore possible that an holiday
from a drug could allow reversion to a previous epigenetic
profile or could facilitate re-emersion of sensitive clones.
To our knowledge few studies evaluated role of treatment
holiday (or intermittent therapy) and chemotherapy free-
interval (CFI).
Studies evaluating efficacy and feasibility of
chemotherapy administered in a stop-and-go strategy
A retrospective study analyzed reintroduction of FOLFOX
in 29 patients affected by mCRC after a break in treatment
or disease progression after another regimen. Six patients
achieved an objective response, corresponding to a
rate of 20.7%; among patients who received no inter-
vening chemotherapy, the objective response rate was
31%, whereas for patients who received intervening
chemotherapy the objective response rate was 12%. Five
of the responses were observed among patients who had
previously responded to FOLFOX treatment, whereas one
response occurred in a patient who had previous progres-
sion. SD was achieved in 15 patients (52%), including
seven patients (44%) who received no intervening
chemotherapy and eight (62%) who received interveningchemotherapy. Clinical benefit was observed in 73% of
cases, progression free survival (PFS) was 4.2 months, and
OS was 9.7 months [37].
The OPTIMOX 1 study also assessed the role of
reintroduction of oxaliplatin in a stop and go strategy.
This study compared treatment with FOLFOX4 until
progression with FOLFOX7 for 6 cycles, followed by
maintenance with leucovorin–5-FU alone and FOLFOX7
reintroduction for a further 6 cycles. Six hundred
twenty patients were enrolled, median PFS and OS
were 9.0 and 19.3 months, respectively, in patients treated
with FOLFOX4 compared with 8.7 and 21.2 months,
respectively, in patients treated with FOLFOX7 in a
stop-and-go strategy (P = not significant). Oxaliplatin was
reintroduced in only 40.1% of the patients but achieved
responses or stabilizations in 69.4% of these patients.
Results show that ceasing oxaliplatin after 6 cycles,
followed by leucovorin–5-FU alone, achieves RR, PFS, and
OS equivalent to that with continuing oxaliplatin until
progression or toxicity [38].
This data showed that treatment holiday is not associ-
ated with worsen outcome and delay presentation of
cumutalive toxicity from oxaliplatin. However this trial do
not assess the efficacy of oxaliplatin reintroduction after
additional lines of therapy (ie, irinotecan and anti-EGFR
or anti-VEGF therapy) and do not analyze the role of a
real treatment holiday.
The OPTIMOX 2 phase II trial randomised 216
patients to receive fluorouracil maintenance between
FOLFOX administration versus a treatment holiday. The
primary objective was the duration of disease control
(DDC), calculated as the sum of the duration of PFS
induced with the initial FOLFOX therapy and with the
subsequent reintroduction of FOLFOX. But most
importantly, after induction of a response, metastases
were allowed to progress back to baseline levels before
FOLFOX was reintroduced.
It was observed that continuing treatment with a main-
tenance chemotherapy led to a longer PFS, compared with
pausing treatment (8.7 months vs 6.9 months, P = 0.009)
but overall survival data were not available [39,40]. DDC
was almost identical in both arms (12.9 months vs
11.7 months, P not significant and duration of CFI seemed
to depend on different clinical prognostic factors including
Eastern Cooperative Oncology Group performance status,
lactate dehydrogenase and alkaline phosphatase levels,
Tonini et al. Journal of Experimental & Clinical Cancer Research 2013, 32:92 Page 5 of 8
http://www.jeccr.com/content/32/1/92number of metastatic sites. These data showed the possi-
bility of identifying a favourable prognosis group which
could benefit from an intermittent strategy.
The COIN phase III study randomized 1630 patients
with untreated metastatic colorectal cancer to receive
either continuous oxaliplatin and fluoropyrimidine
combination (arm A), continuous chemotherapy plus
cetuximab (arm B), or intermittent (arm C) chemother-
apy. In arms A and B, treatment continued until develop-
ment of progressive disease, cumulative toxic effects, or
the patient chose to stop. In arm C, patients who had not
progressed after six cycles of chemotherapy started a treat-
ment holiday until evidence of disease progression, when
the same treatment was restarted. Median survival
was 15.8 months in arm A vs 14.4 months in arm C
(hazard ratio 1.084, 80% CI 1.008–1.165). In the
per-protocol population, more patients on continuous
than on intermittent treatment had grade 3 or worse
haematological toxic effects (15% vs 12%), whereas nausea
and vomiting were more common on intermittent treat-
ment (2% vs 8%). Other grade 3 or worse toxicities
(such as peripheral neuropathy and hand–foot syndrome)
were more frequent on continuous than on intermittent
treatment [41].
Studies evaluating efficacy and feasibility of biological
therapy administered during chemotherapy-free interval
The NORDIC VII multicenter phase III trial randomly
assigned 571 previously untreated patients to receive the
standard Nordic FLOX, cetuximab and FLOX, or cetuxi-
mab combined with intermittent FLOX. Median PFS
was 7.9, 8.3, and 7.3 months for the three arms, respect-
ively (not significantly different). But OS was almost iden-
tical for the three groups (20.4, 19.7, 20.3 months,Table 3 Clinical evidences evaluating different strategies for
EGFR therapy rechallenge
- A multicenter phase II prospective
therapy after an intervening che
- A phase II prospective study did
on prior cetuximab-based therapy
Chemotherapy stop-and go strategy
- OPTIMOX 1 study shows that cea
achieves RR, PFS, and OS equivale
- OPTIMOX 2 study shows that co
PFS, compared with pausing treat
- COIN study did not show a non
treatment holiday significantly red
Biological treatment of
chemotherapy-free interval
- NORDIC VIII phase III trial showed
to intermittent treatment [42].
- COIN B phase II trial showed tha
interval and PFS [43].
- MACRO TTD phase III trial confirm
predefined period of chemotherap
- CAIRO 3 phase III trial showed th
administrated after chemotherapy
treatment holiday strategy [45].respectively), and confirmed RR were 41%, 49%, and 47%,
respectively [42].
The phase II COIN-B trial randomized patients to
receive cetuximab and chemotherapy (Arm D) in an
intermittent schedule versus intermittent chemotherapy
with continuous cetuximab administration (Arm E). Upon
RECIST progression on either arm, the same chemother-
apy plus cetuximab was restarted and continued until
progression. Continuous cetuximab administration as
maintenance was associated with a longer CFI and longer
PFS (5,1 and 13,7 months respectively vs 3,7 and
12 months in the arm D) [43].
The MACRO TTD phase III trial randomized 480
previously untreated mCRC patients to receive 6 cycles
of bevacizumab and Xelox followed by Xelox and
bevacizumab (arm A) or bevacizumab alone (Arm B).
There were not statistically significant differences in PFS
and OS between the 2 arms [44]. This study confirmed
the efficacy of a maintenance therapy with bevacizumab
after a predefined period of chemotherapy induction but
did not investigated the role of bevacizumab maintenance
in a stop-and-go strategy with a subsequent reintroduc-
tion of the same chemotherapy when disease progression
occurs.
In the ongoing AIO study, maintenance treatment with
capecitabine or 5-FU/folinic acid and bevacizumab is
compared with bevacizumab alone or no maintenance
treatment in subjects with inoperable and non-progressive
metastatic colorectal cancer after first line induction treat-
ment for 24 weeks with a fluoropyrimidine-, oxaliplatin-
and bevacizumab-based chemotherapy. Reinduction treat-
ment will be done in case of progression (Table 3).
These studies do not allow a clear indication on what
is the best option between treatment holiday (defined astreatment of mCRC
study confirmed the activity of cetuximab rechallenge plus irinotecan-based
motherapy [30]
not show any response to panitumumab administrated after progression
[31]
sing oxaliplatin after 6 cycles, followed by leucovorin–5-FU alone,
nt to that with continuing oxaliplatin until progression or toxicity [38]
ntinuing treatment with a maintenance chemotherapy led to a longer
ment [39]
inferiority of chemotherapy free interval versus continuous treatment but
uced cumulative toxic effects, and improved quality of life [41]
that cetuximab maintenance do not improve survival data comparing
t cetuximab maintenance significantly improved chemotherapy free
ed the efficacy of a maintenance therapy with bevacizumab after a
y induction [44].
at bevacizumab and de-escalated chemotherapy maintenance
and bevacizumab induction significantly improves OS comparing to a
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val with a period of maintenance therapy, and more
prospective trial are warranted.Conclusions
The role of rechallenge therapy in third-line or fourth-line
setting in mCRC is not defined but it could be a possibility
for fit patients who do not have any other valid options.
Few clinical studies evaluated the role of targeted
therapies rechallenge and up to date there are no
convincing predictive factors suggesting which drug
should be readministered. This choice should be based
on several reasonable factors: best response to prior treat-
ment before progression (prolonged stable disease,
partial response or complete response), residual toxicity
(especially in case of oxaliplatin reintroduction), duration
of treatment holiday.
In our opinion, intermittent treatment could be an
important strategy in management of mCRC patient
when there is not the purpose of gaining an important
tumour shrinkage, for avoiding cumulative toxicity and
for maintaining chemotherapy sensitiveness even if there
is not a clear evidence in prolonging OS compared to
the intensive treatment.
Moreover, few clinical studies assessed the role of
rechallenge in the era of targeted therapy and no studies
evaluated the activity of bevacizumab as a rechallenge
therapy (both as a monotherapy or in combination with
standard chemotherapy) so far. However, it has been
demonstrated that targeted therapy could enhance
sensitivity to both chemotherapy and radiotherapy [46].
Brite and TML study showed a benefit in the use of
bevacizumab beyond disease progression. However, in this
case, we cannot regard to bevacizumab administration as
a real rechallenge, as there was no treatment interruption
after disease progression or any intervening therapy.
Further clinical studies should enquire the role of bevaci-
zumab retreatment and the importance of angiogenesis
control in heavily pretreated mCRC patients as a possible
mechanism of restoring sensitivity to re-administration of
standard chemotherapy. However this evaluation should
take into account several new evidences: 1) recent studies
proved the efficacy of bevacizumab as maintenance therapy
without any interruption, 2) there are data suggesting the
efficacy of bevacizumab beyond progression [47-49]; 3)
preclinical evidences demonstrated that there is a revers-
ible tumor growth acceleration following bevacizumab
interruption [50] 4) a phase III trial showed that
bevacizumab and de-escalated chemotherapy mainten-
ance administrated after chemotherapy and bevacizumab
induction significantly improved OS comparing to a
treatment holiday strategy (21.7 vs 17.9 months, p = 0,02)
[45]. So a real standard strategy regarding bevacizumabadministration through several lines of treatment of
mCRC patients is still not defined.
In this sense, to date, there are no phase III trial com-
paring the bevacizumab rechallenge strategy (bevacizu-
mab readministration after a treatment holiday) with
bevacizumab-alone maintenance and with a de-escalated
chemotherapy and bevacizumab maintenance. The
ongoing AIO study could suggest which is the better
strategy applying to bevacizumab administration.
Moreover, clinical trials evaluating predictive factors of
response to chemotherapy and biologic agents rechallenge
or to intermittent therapies are warranted in order to
select patients, avoid possible side effect and useless waste
of resources. In addition, randomized trials should be
performed to understand the clinical impact of rechallenge
and intermittent treatment strategies in advanced CRC
patients.
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